Skip to main content
Premium Trial:

Request an Annual Quote

ThermaGenix Licenses PCR Technologies From Brandeis University

NEW YORK (GenomeWeb) – ThermaGenix said Saturday that it has exclusively licensed technologies from Brandeis University that employ PCR to enhance detection and analysis of nucleic acids, including both DNA and RNA.

For more than 20 years, Brandeis professor Lawrence Wangh and his colleagues "have investigated and improved virtually every aspect of PCR and RT-PCR amplification of DNA and RNA," ThermaGenix said. The firm noted that the university’s additive reagents eliminate mis-priming "before, during, and after PCR and RT-PCR amplification and thereby increase assay quality, quantitative accuracy, sensitivity, and multiplexing capabilities."

The platform technologies it has licensed are applicable to diagnosis of human cancers, infectious diseases, and genomic analysis of virtually all forms of life, ThermaGenix said. In May, the firm will begin marketing its Therma-Stop and Therma-Go products, which it said enhance the sensitivity and accuracy of conventional PCR reactions.

ThermaGenix noted that it will also use additional methods and reagents it has licensed from Brandeis to construct molecular assays for species identification and molecular diagnostics tests for cancer-related mutations in DNA recovered from blood plasma.

"These new products — as well as other technologies ThermaGenix has licensed and will commercialize — will make crucial medical procedures faster, more effective, and more affordable," ThermaGenix President Peter Coassin said in a statement. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.